Teva and Polpharma Biologics Announce Global Licensing Agreement for A Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
Latest news
3rd of August 2022
U.S. Food and Drug Administration (FDA) approves FYB201/CIMERLITM* (ranibizumab-eqrn), the first and only biosimilar interchangeable with Lucentis®**
CIMERLI™ is the only biosimilar approved for all five Lucentis® indications
Commercially available in 0.3 mg and 0.5 mg dosages
U.S. commercial launch by Coherus BioSciences, Inc. expected in early October 2022
Amsterdam,...
Polpharma Biologics announced today that the U.S. Food and Drug Administration (FDA) has accepted the first-ever Biol...
Warszawa, 18 lipca 2022 r.
Polpharma Biologics, polska firma biotechnologiczna zajmująca się rozwojem i produkcją leków biologicznych ogłosiła, że Europejska Agencja Leków (European Medicines Agency – EMA) przyjęła wniosek (Marketing Authorization Application – MAA) o wydanie pozwolenia na dopuszczenie do obrotu na terenie Unii Europejskiej – leku biopodobnego zawierającego przeciwciało...
MHRA’s authorization for BIOEQ’s biosimilar in the United Kingdom.
We are pleased to share last week’s news on the approval of the marketing authorization application of BIOEQ’s Lucent...
The reference product is a monoclonal anti-angiogenic antibody fragment (Fab) that has been approved to treat the "we...
Zug, Switzerland – MS Pharma has signed an exclusive licensing and supply agreement with Bioeq AG, Switzerland, the P...
Bioeq has received notification by the U.S. Food and Drug Administration (FDA) that the biologics license application...
The new roles come on top of significant growth at the company in the last two years, with an additional 300 employee...
Polpharma Biologics Group announces that its joint venture company with Santo Holding (Strüngmann Group), Bioeq, has...
